-+ 0.00%
-+ 0.00%
-+ 0.00%

AlphaTON Capital Preclinical Mesothelioma Data Demonstrates Anti-Tumor Activitiy In Epithelial And Non-epithelioid Mesothelioma Models, Reducing Tumor PD-L1 And pCREB In Human Epithelioid Mesothelioma Cell System

Benzinga·10/27/2025 12:10:00
Listen to the news

AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on Saturday at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The poster showed that selective A2B receptor inhibition produces direct anti-tumor activity in both epithelial and non-epithelioid mesothelioma models, reduces tumor PD-L1 alongside decreased pCREB in a human epithelioid mesothelioma cell system, and that TT-4 monotherapy outperformed anti-PD-1 with additional activity in combination. TT-4 remains on track for first-patient dosing in Q1 2026.